Donna Ambrosino
Fortuna: 84 114 $ al 31/07/2026
Fortuna: 84 114 $ al 31/07/2026
Donna Marie Ambrosino currently works at Clover Biopharmaceuticals Ltd., as Non-Executive Director from 2022.
Dr. Ambrosino also formerly worked at Visterra, Inc., as Chief Medical Officer from 2012 to 2014 and Harvard Medical School, as Associate Professor.
Dr. Ambrosino received her undergraduate degree from Harvard University and doctorate degree from Dartmouth Medical School.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 15/06/2026 | 329.796 ( 0,03 % ) | 84 114 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CLOVER BIOPHARMACEUTICALS, LTD. | Director/Miembro de la Junta | 17/06/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| VISTERRA INC | Director Técnico/Científico/I+D | 01/01/2014 |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Visterra, Inc.
Visterra, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dartmouth Medical School
Dartmouth Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.